MedTrace Logo

Efficacy and Safety of AZD7009 in the Treatment of Atrial Fibrillation

NCT00255281 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2007-12-06

No results posted yet for this study

Summary

The current study is designed to assess the efficacy and safety of iv AZD7009 in conversion from AF

Conditions

Interventions

DRUG

AZD7009, no generic name available

Sponsors & Collaborators

Principal Investigators

  • AstraZeneca AZD7009 Midical Science Director, MD · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Completion
2006-05-31

Countries

  • Denmark
  • Finland
  • Germany
  • Hungary
  • Netherlands
  • Norway
  • Poland
  • Sweden

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00255281 on ClinicalTrials.gov